Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones

14.08.2023 - Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD) ISELIN, N.J., Aug. 14, 2023 (GLOBE ...

Related Keywords

United States ,Japan ,Ukraine ,United Kingdom ,China ,Russia ,Harriet Ullman ,Jenene Thomas ,Committee For Medicinal Products Human Use ,Amerisourcebergen ,Alliance Healthcare ,Lavoie Health Science ,Fujifilm ,Exchange Commission ,Outlook Therapeutics Inc ,Aji Bio Pharma Services ,Upcoming Anticipated ,Planning Underway ,Support Potential Approval ,First Ophthalmic Formulation ,Outlook Therapeutics ,Pre Launch Preparations Proceeding ,Marketing Authorization Application ,Medicinal Products ,Human Use ,Syntone Biopharma ,Special Protocol Assessments ,Fiscal Third Quarter Ended June ,Outlook Therapeutic ,Annual Report ,